PAVmed(PAVM) - 2025 Q4 - Annual Results

Financial Performance - PAVmed completed a $30 million Series D preferred stock offering and a $15 million senior secured note financing, eliminating all previously outstanding convertible securities[8] - Lucid Diagnostics recognized $1.5 million in EsoGuard Esophageal DNA Test revenue for Q4 2025 and processed 3,664 EsoGuard tests[8] - Operating expenses for Q4 2025 were approximately $6.9 million, including stock-based compensation expenses of $0.3 million[8] - GAAP net loss attributable to common stockholders for Q4 2025 was approximately $1.8 million, or $(2.05) per common share on a diluted basis[8] - Non-GAAP adjusted loss for Q4 2025 was approximately $0.9 million, or $(1.05) per common share[8] - PAVmed had cash and cash equivalents of $1.5 million as of December 31, 2025, compared to $1.2 million as of December 31, 2024[10] Product Development and Regulatory Progress - Veris Health is progressing its implantable physiological monitor toward a planned late 2026 FDA 510(k) submission[8] - PAVmed relaunched its medical device portfolio under new leadership, appointing Joseph Virgilio as Chief Business Officer of Medical Devices[8] - Veris Health's strategic engagement with The Ohio State University's James Cancer Hospital is well underway, with full integration into the hospital's electronic health record system now complete[8] Market and Operational Risks - PAVmed and Lucid's management acknowledges risks and uncertainties that could impact future results, including stock price volatility and market conditions[19] - The companies are focused on advancing their products through regulatory submission, which involves significant costs and time[19] - There is uncertainty regarding whether regulatory authorities will approve PAVmed and Lucid's products based on clinical and preclinical study results[19] - Market acceptance of PAVmed and Lucid's products post-approval is a critical factor for future success[19] - The ability to raise additional funding is essential for PAVmed and Lucid to support their operations and product development[19] - New risks and uncertainties may emerge, making it challenging to predict future outcomes[19] Strategic Partnerships - Lucid Diagnostics was awarded a U.S. Department of Veterans Affairs contract for EsoGuard, expanding access to approximately nine million veterans[8]